Is the Cicada Variant More Dangerous? 7 Key Facts Every American Should Know in 2026

Hi there! 👋

If you’ve been scrolling through the news lately and seeing the word “Cicada” pop up next to “COVID,” you’re probably wondering — should I be worried? Is this new variant actually more dangerous than what we’ve dealt with before?

We get it. After years of pandemic fatigue, the last thing anyone wants is another wave of anxiety about a new strain. So let’s cut through the noise. We’ve pulled together the 7 most important facts about the COVID-19 Cicada variant — backed by the latest data from the CDC, WHO, and leading virologists — so you can make informed decisions for yourself and your family.

The COVID-19 Cicada variant, officially designated BA.3.2, is a highly mutated strain of SARS-CoV-2 that has recently grabbed the attention of global health officials.

It was first identified in South Africa in November 2024 and first detected in a U.S. traveler in June 2025 — a traveler returning from the Netherlands at San Francisco International Airport, to be exact.

So, why “Cicada”? The nickname was coined by evolutionary biologist T. Ryan Gregory, Ph.D. from the University of Guelph — the same researcher who named other variants like “Stratus” and “Pirola.” Just like the actual cicada insect, which stays underground for years before emerging in massive numbers, BA.3.2 circulated quietly since late 2024 before finally showing up on health officials’ radars in early 2026.

That sheer volume of mutations is what’s making scientists pay close attention. More mutations in the spike protein can mean the virus looks different to your immune system — and may be better at slipping past existing immunity from vaccines or prior infection.

The Cicada COVID variant is no longer just a regional concern. As of late March 2026, BA.3.2 has been detected in at least 23 countries and found in wastewater surveillance samples from 132 monitoring sites across at least 25 U.S. states.

Europe is where things are most noticeable. In parts of Northern Europe — including Germany, Denmark, and the Netherlands — the Cicada variant accounts for roughly 30% of COVID-19 sequences as of January 2026. That’s a big footprint for a variant that was barely on anyone’s radar just months before.

In the U.S., BA.3.2 is not yet dominant. The current leading strain is still XFG (“Stratus”), accounting for about 53% of wastewater samples, while BA.3.2 sits at around 3.7% as of mid-March 2026, according to Stanford’s WasteWaterSCAN tool.

However, experts warn that the European trend is a preview of what could happen here. Low vaccination rates and reduced public health efforts leave the U.S. more exposed than many would like to admit.

This is the question everyone’s asking — and the honest, evidence-based answer right now is: no, not based on current data.

Despite its alarming number of mutations, the Cicada variant does not appear to cause more severe illness or higher mortality than other strains currently in circulation. There is no evidence from countries where it is already spreading widely — like Germany and Denmark — that it is driving up hospitalizations or deaths at unusual rates.

Epidemiologist Dr. Syra Madad echoed this cautious tone, noting that so far there is no evidence BA.3.2 is causing more severe illness at a population level. That said, the situation is still evolving — and COVID-19 has a way of surprising us.

The concern isn’t necessarily about severity right now. It’s about immune escape — the variant’s ability to slip past protection built up from vaccines or prior infections. More on that in a moment.

Here’s some genuinely reassuring news: the Cicada variant symptoms are largely similar to those seen with other recent COVID strains. You don’t need a new checklist — the old one still applies.

According to the CDC’s 2026 guidance, common COVID-19 symptoms — including those associated with BA.3.2 — include:

• Fever or chills
• Cough (dry or with mucus)
• Fatigue and body aches
• Runny nose or congestion
• Headache
• Sore throat — some patients report an intense “razorblade throat” sensation
• Nausea or vomiting
• Shortness of breath in more serious cases
• Loss of taste or smell (less common with newer variants)

One symptom worth highlighting is what’s being called a “razorblade throat” — an unusually intense sore throat reported by a growing number of COVID patients in 2026. Dr. Robert H. Hopkins Jr. confirmed that severe sore throat is among the common symptoms associated with the current wave of COVID infections.

Symptoms can vary significantly from person to person and usually resolve on their own with supportive care — rest, fluids, and over-the-counter medications. But elderly individuals, immunocompromised people, and those with underlying health conditions remain at greater risk of serious illness and should consult a doctor early if symptoms develop.

This is the big question — and the answer is more nuanced than a simple yes or no.

The 2025–2026 COVID-19 vaccines available in the U.S. were formulated to target variants from the JN.1 lineage. BA.3.2 (Cicada), however, has diverged significantly from that lineage — those 70+ spike protein mutations mean the variant may look quite different to the antibodies your immune system built up from vaccination.

Laboratory studies published in The Lancet found that current vaccines produced a noticeably weaker immune response against BA.3.2 compared to other circulating strains like XFG. However, experts stress that this doesn’t mean vaccines are useless — far from it.

Dr. Donald Milton, a respiratory virus expert at the University of Maryland, pointed out that vaccines likely still protect against severe illness, even if they’re less effective at preventing infection. Your immune system isn’t starting from scratch — there’s still cross-reactivity, meaning it recognizes enough of the virus to mount a meaningful defense.

The scientific community is in a state of watchful caution — not panic. Here’s a quick roundup of what leading voices are actually saying:

The consensus? Stay informed, don’t overreact, but don’t get complacent either. The scientific community is doing its job — actively tracking BA.3.2 through wastewater surveillance, genomic sequencing, and real-world patient data.

Good news: protecting yourself from the Cicada variant doesn’t require anything dramatically new. The basics still work — and they work well. Here’s your updated action plan for 2026:

• Stay up to date with vaccines and boosters — they still significantly reduce the risk of severe illness and hospitalization
• Stay home if you’re sick — don’t expose others, especially vulnerable people
• Get tested if you develop symptoms — confirm with a negative test before returning to normal activities
• Wear a high-quality N95 or KN95 mask in crowded or high-risk indoor settings
• Improve ventilation at home and work — open windows, use HEPA air purifiers
• Wash your hands frequently — good hygiene remains one of the most effective tools we have
• Talk to your doctor early if symptoms worsen — antiviral treatments like Paxlovid remain effective against Cicada
• Rest and stay hydrated — give your body the best conditions to recover
• Avoid close contact with vulnerable individuals if you’ve been recently exposed

One especially reassuring piece of information: COVID antiviral drugs still work against BA.3.2. Dr. García-Sastre from Mount Sinai confirmed that existing antivirals remain sensitive to the Cicada variant — so if you get sick and seek care promptly, effective treatment is available.

As we head into warmer months with more travel and social gatherings, awareness and action are your best tools. As Neil Maniar from Northeastern University noted, COVID is now part of our day-to-day lives — much like the flu. Treat it with the same combination of awareness, common sense, and appropriate caution.

This article is for informational purposes only and does not constitute medical advice.
Always consult a qualified healthcare provider for personal medical guidance.
Sources: CDC MMWR March 2026, WHO Variant Tracking, Johns Hopkins Bloomberg School of Public Health, National Foundation for Infectious Diseases, Northeastern University, The Lancet.